FATE Stock Analysis: Fate Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 317m USD | 12M Return: 132.5% | US31189P1021 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 4.47M
Qual. Beats: 0
Rev. Trend: -81.8%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies, primarily CAR-engineered NK and T-cell product candidates, for cancer and immune disorders. Its pipeline includes preclinical and early-stage programs such as FT836 (multiple tumor types), FT522 (B-cell lymphoma and autoimmunity), and CAR T-cell candidates FT819 (systemic lupus erythematosus), FT839 (complex autoimmune diseases), and FT825 (solid tumors). The company has a collaboration and option agreement with Ono Pharmaceutical for off-the-shelf, iPSC-derived CAR T-cell product candidates targeting solid tumors. Incorporated in 2007 and headquartered in San Diego, California, Fate Therapeutics operates in the biotechnology subsector, and as a clinical-stage company, it has not yet commercialized any approved products, relying instead on partnerships and capital markets to fund its research and development activities.
- FT522 and FT819 clinical data readouts drive stock volatility
- Ono Pharmaceutical partnership milestones and solid tumor collaboration progress
- Cash burn and share dilution risk amid clinical stage operations
| Net Income: -129.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA -5.01 > 1.0 |
| NWC/Revenue: 2.36k% < 20% (prev 1.65k%; Δ 706.3% < -1%) |
| CFO/TA -0.36 > 3% & CFO -103.1m > Net Income -129.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.85 > 1.5 & < 3 |
| Outstanding Shares: last quarter (120.0m) vs 12m ago 1.40% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.85% > 50% (prev 3.34%; Δ -1.50% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.52 (Total Current Assets 179.5m - Total Current Liabilities 30.7m) / Total Assets 284.9m |
| B: -5.49 (Retained Earnings -1.57b / Total Assets 284.9m) |
| C: -0.38 (EBIT TTM -129.9m / Avg Total Assets 341.8m) |
| D: 1.71 (Book Value of Equity 179.7m / Total Liabilities 105.2m) |
| Altman-Z'' = -15.25 = D |
| DSRI: 0.62 (Receivables 704k/2.41m, Revenue 6.32m/13.3m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.33 (AQ_t 0.04 / AQ_t-1 0.11) |
| SGI: 0.47 (Revenue 6.32m / 13.3m) |
| TATA: -0.09 (NI -129.9m - CFO -103.1m) / TA 284.9m) |
| Beneish M = -4.12 (Cap -4..+1) = AAA |
As of August 20, 2026, the stock is trading at USD 2.65 with a total of 1,216,759 shares traded. Over the past week, the price has changed by -2.57%, over one month by -5.19%, over three months by +40.21% and over the past year by +132.46%.
Current recommended Stop Loss: 2.30 (which is 13.2% or 1.8 ATR below the current price).
Fate Therapeutics has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy FATE.
- StrongBuy: 5
- Buy: 1
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 5.4 | 104.2% |
P/S = 50.077
P/B = 1.7902
Revenue TTM = 6.32m USD
EBIT TTM = -129.9m USD
EBITDA TTM = -117.4m USD
Long Term Debt = 72.0m USD (estimated: total debt 76.8m - short term 4.74m)
Short Term Debt = 4.74m USD (from shortTermDebt, last quarter)
Debt = 76.8m USD (from shortLongTermDebtTotal, last quarter) (leases 76.8m already included)
Net Debt = -98.0m USD (calculated: Debt 76.8m - CCE 174.8m)
Enterprise Value = 219.0m USD (317.0m + Debt 76.8m - CCE 174.8m)
Interest Coverage Ratio = unknown (Ebit TTM -129.9m / Interest Expense TTM 0.0)
EV/FCF = -2.15x (Enterprise Value 219.0m / FCF TTM -101.7m)
FCF Yield = -46.45% (FCF TTM -101.7m / Enterprise Value 219.0m)
FCF Margin = -1.61k% (FCF TTM -101.7m / Revenue TTM 6.32m)
Net Margin = -2.06k% (Net Income TTM -129.9m / Revenue TTM 6.32m)
Gross Margin = unknown ((Revenue TTM 6.32m - Cost of Revenue TTM 35.6m) / Revenue TTM)
Tobins Q-Ratio = 0.77 (Enterprise Value 219.0m / Total Assets 284.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 76.8m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -102.6m (EBIT -129.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.29 (Total Current Assets 179.5m / Total Current Liabilities 34.0m)
Debt / Equity = 0.43 (Debt 76.8m / totalStockholderEquity, last quarter 179.7m)
Debt / EBITDA = 0.83 (negative EBITDA) (Net Debt -98.0m / EBITDA -117.4m)
Debt / FCF = 0.96 (negative FCF - burning cash) (Net Debt -98.0m / FCF TTM -101.7m)
Total Stockholder Equity = 220.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.01% (Net Income -129.9m / Total Assets 284.9m)
RoE = -58.89% (Net Income TTM -129.9m / Total Stockholder Equity 220.6m)
RoCE = -44.39% (EBIT -129.9m / Capital Employed (Equity 220.6m + L.T.Debt 72.0m))
RoIC = -39.68% (negative operating profit) (NOPAT -102.6m / Invested Capital 258.7m)
WACC = 11.58% (E(317.0m)/V(393.8m) * Re(14.38%) + D(76.8m)/V(393.8m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 14.38% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 75.94 | Cagr: 9.13%
[DCF] Fair Price = unknown (Cash Flow -101.7m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.23 | # QB: 0
Revenue Correlation: -81.75 | Revenue CAGR: -62.94% | SUE: -0.14 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.26 | Chg30d=+0.83% | Revisions=+25% | Analysts=9
EPS current Year (2026-12-31): EPS=-1.04 | Chg30d=-1.36% | Revisions=-25% | GrowthEPS=+9.7% | GrowthRev=-21.1%
EPS next Year (2027-12-31): EPS=-0.99 | Chg30d=-7.04% | Revisions=-25% | GrowthEPS=+4.8% | GrowthRev=-0.2%
[Analyst] Revisions Ratio: -17% (up=1, down=2)